Positive Topline Results Reported from Bristol Myers Squibb’s Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme’s ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Posted on by

BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO, Oct. 19, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Bristol Myers Squibb (BMS)…